Maxim Positive on Inovio Pharma's (INO) Zika Virus Vaccine Collaboration; Reaffirms at 'Buy'

January 22, 2016 10:03 AM

Maxim affirms Inovio Pharmaceuticals (Nasdaq INO) with a Buy rating and $14 price target after the company announced a new ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found